Literature DB >> 11572989

WWOX: a candidate tumor suppressor gene involved in multiple tumor types.

A J Paige1, K J Taylor, C Taylor, S G Hillier, S Farrington, D Scott, D J Porteous, J F Smyth, H Gabra, J E Watson.   

Abstract

We previously reported the construction of a P1-derived artificial chromosome (PAC) contig encompassing a set of homozygous deletions of chromosome 16q23-24.1 found in primary ovarian tumor material and several tumor cell lines. Using these PAC clones in a cDNA selection experiment, we have isolated a Sau3A fragment homologous to the WWOX transcript (GenBank accession no. ) from normal human ovarian surface epithelial (HOSE) cells. We demonstrate the homozygous deletion of WWOX exons from ovarian cancer cells and three different tumor cell lines. We also identify an internally deleted WWOX transcript from a further primary ovarian tumor. In three of these samples the deletions result in frameshifts, and in each case the resulting WWOX transcripts lack part, or all, of the short chain dehydrogenase domain and the putative mitochondrial localization signal. Sequencing revealed several missense polymorphisms in tumor cell lines and identified a high level of single nucleotide polymorphism (SNP) within the WWOX gene. This evidence strengthens the case for WWOX as a tumor suppressor gene in ovarian cancer and other tumor types.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572989      PMCID: PMC58744          DOI: 10.1073/pnas.191175898

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

1.  FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations.

Authors:  K M Fong; E J Biesterveld; A Virmani; I Wistuba; Y Sekido; S A Bader; M Ahmadian; S T Ong; F V Rassool; P V Zimmerman; G Giaccone; A F Gazdar; J D Minna
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

2.  Chromosomal fragile site FRA16D and DNA instability in cancer.

Authors:  M Mangelsdorf; K Ried; E Woollatt; S Dayan; H Eyre; M Finnis; L Hobson; J Nancarrow; D Venter; E Baker; R I Richards
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

3.  A 700-kb physical map of a region of 16q23.2 homozygously deleted in multiple cancers and spanning the common fragile site FRA16D.

Authors:  A J Paige; K J Taylor; A Stewart; J G Sgouros; H Gabra; G C Sellar; J F Smyth; D J Porteous; J E Watson
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

4.  Loss of heterozygosity at 3p14.2 in clear cell renal cell carcinoma is an early event and is highly localized to the FHIT gene locus.

Authors:  M Velickovic; B Delahunt; S K Grebe
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

5.  Role of FHIT in human cancer.

Authors:  C M Croce; G Sozzi; K Huebner
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

6.  WWOX, a novel WW domain-containing protein mapping to human chromosome 16q23.3-24.1, a region frequently affected in breast cancer.

Authors:  A K Bednarek; K J Laflin; R L Daniel; Q Liao; K A Hawkins; C M Aldaz
Journal:  Cancer Res       Date:  2000-04-15       Impact factor: 12.701

7.  Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: refining a putative tumor suppressor gene region.

Authors:  T Chen; A Sahin; C M Aldaz
Journal:  Cancer Res       Date:  1996-12-15       Impact factor: 12.701

8.  Cancer-specific chromosome alterations in the constitutive fragile region FRA3B.

Authors:  K Mimori; T Druck; H Inoue; H Alder; L Berk; M Mori; K Huebner; C M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

9.  Muir-Torre-like syndrome in Fhit-deficient mice.

Authors:  L Y Fong; V Fidanza; N Zanesi; L F Lock; L D Siracusa; R Mancini; Z Siprashvili; M Ottey; S E Martin; T Druck; P A McCue; C M Croce; K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

10.  Deletion mapping of chromosome 16q in hepatocellular carcinoma.

Authors:  Z Piao; C Park; J J Kim; H Kim
Journal:  Br J Cancer       Date:  1999-05       Impact factor: 7.640

View more
  89 in total

1.  Frequent attenuation of the WWOX tumor suppressor in osteosarcoma is associated with increased tumorigenicity and aberrant RUNX2 expression.

Authors:  Kyle C Kurek; Sara Del Mare; Zaidoun Salah; Suhaib Abdeen; Hussain Sadiq; Suk-Hee Lee; Eugenio Gaudio; Nicola Zanesi; Kevin B Jones; Barry DeYoung; Gail Amir; Mark Gebhardt; Matthew Warman; Gary S Stein; Janet L Stein; Jane B Lian; Rami I Aqeilan
Journal:  Cancer Res       Date:  2010-06-08       Impact factor: 12.701

2.  A multi-exon deletion within WWOX is associated with a 46,XY disorder of sex development.

Authors:  Stefan White; Jacqueline Hewitt; Erin Turbitt; Yvonne van der Zwan; Remko Hersmus; Stenvert Drop; Peter Koopman; Vincent Harley; Martine Cools; Leendert Looijenga; Andrew Sinclair
Journal:  Eur J Hum Genet       Date:  2011-11-09       Impact factor: 4.246

3.  Deletion and mutation of WWOX exons 6-8 in human non-small cell lung cancer.

Authors:  Yulong Zhou; Yongjian Xu; Zhenxiang Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

4.  Characterization of the tumor suppressor gene WWOX in primary human oral squamous cell carcinomas.

Authors:  Flávio J Pimenta; Dawidson A Gomes; Paolla F Perdigão; Alvimar A Barbosa; Marco A Romano-Silva; Marcus V Gomez; C Marcelo Aldaz; Luiz De Marco; Ricardo S Gomez
Journal:  Int J Cancer       Date:  2006-03-01       Impact factor: 7.396

5.  WWOX protein expression in normal human tissues.

Authors:  Maria I Nunez; John Ludes-Meyers; C Marcelo Aldaz
Journal:  J Mol Histol       Date:  2006-08-29       Impact factor: 2.611

Review 6.  Common fragile genes and digestive tract cancers.

Authors:  Tamotsu Kuroki; Yoshitsugu Tajima; Jyunichiro Furui; Takashi Kanematsu
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

7.  Characterizing WW domain interactions of tumor suppressor WWOX reveals its association with multiprotein networks.

Authors:  Mohammad Abu-Odeh; Tomer Bar-Mag; Haiming Huang; TaeHyung Kim; Zaidoun Salah; Suhaib K Abdeen; Marius Sudol; Dana Reichmann; Sachdev Sidhu; Philip M Kim; Rami I Aqeilan
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

8.  Conditional inactivation of the mouse Wwox tumor suppressor gene recapitulates the null phenotype.

Authors:  Suhaib K Abdeen; Sara Del Mare; Sadeeq Hussain; Muhannad Abu-Remaileh; Zaidoun Salah; John Hagan; Maysoon Rawahneh; Xin-An Pu; Stacey Russell; Janet L Stein; Gary S Stein; Jane B Lian; Rami I Aqeilan
Journal:  J Cell Physiol       Date:  2013-07       Impact factor: 6.384

9.  Low levels of WWOX protein immunoexpression correlate with tumour grade and a less favourable outcome in patients with urinary bladder tumours.

Authors:  D Ramos; M Abba; J A López-Guerrero; J Rubio; E Solsona; S Almenar; A Llombart-Bosch; C M Aldaz
Journal:  Histopathology       Date:  2008-04-29       Impact factor: 5.087

Review 10.  WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies.

Authors:  C Marcelo Aldaz; Brent W Ferguson; Martin C Abba
Journal:  Biochim Biophys Acta       Date:  2014-06-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.